| Household Durables Industry | Consumer Discretionary Sector | Pierre Boulud CEO | OTC PINK Exchange | 09074E101 CUSIP |
| FR Country | 14,147 Employees | 10 Jun 2026 Last Dividend | - Last Split | - IPO Date |
bioMérieux S.A., originally known as B-D Mérieux, is a pioneering entity in the field of in vitro diagnostic solutions, standing at the forefront since its inception in 1963. With its headquarters nestled in Marcy l'Etoile, France, the company stretches its influence globally, catering to diverse regions including the Americas, Europe, the Middle East, Africa, and the Asia Pacific. As a subsidiary of Institut Mérieux SA, bioMérieux has carved a niche in diagnosing infectious diseases through advanced diagnostic systems that leverage biological samples such as blood, saliva, and urine. These systems are adept at identifying a broad spectrum of infectious diseases, ranging from bacterial, parasitic to viral infections, thereby facilitating timely and accurate medical interventions.
Apart from its clinical applications, bioMérieux is instrumental in ensuring the microbiological integrity of production environments across the food, pharmaceutical, and cosmetic industries. The company's commitment to innovation is further exemplified through its BIOMÉRIEUX VISION SUITE, a comprehensive suite of software products and services designed for the seamless collection, analysis, and integration of diverse data sources to aid in decisive actions. Furthermore, bioMérieux's extensive portfolio includes designing, manufacturing, and maintaining sophisticated instruments and software, alongside a vast array of reagents for in vitro diagnostic tests, addressing the needs of clinical and hospital laboratories, physicians, blood banks, veterinarians, and industrial control laboratories.